FGP
UTHR icon

Freestone Grove Partners’s United Therapeutics UTHR Stock Holding History

Freestone Grove Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$654K Sell
1,207
-600
-33% -$338K ﹤0.01% 609
2026
Q1 		$1.07M Buy
1,807
+384
+27% +$191K 0.01% 461
2025
Q4 		$693K Buy
+1,423
New +$663K 0.01% 518
2025
Q1 		– Sell
-1,785
Closed -$630K – 801
2024
Q4 		$630K Buy
+1,785
New +$656K 0.01% 347

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Freestone Grove Partners's UTHR Position: Q2 2026 in Review

Freestone Grove Partners reduced its United Therapeutics (UTHR) stake by 33% in Q2 2026, selling an estimated $338K and leaving 1,207 shares worth $654K. The position accounts for ﹤0.01% of the portfolio, ranked #609.

Freestone Grove Partners first reported a position in UTHR in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.07M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Freestone Grove Partners held 1,207 shares of United Therapeutics worth $654K as of Q2 2026.
  • Freestone Grove Partners sold 600 United Therapeutics shares in Q2 2026, an estimated $338K.
  • United Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #609 holding.
  • Freestone Grove Partners first reported a position in United Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Freestone Grove Partners's United Therapeutics position peaked at $1.07M in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.